Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus
Sponsor: MacroGenics
This observational or N/A phase trial investigates West Nile Virus Infection and is currently ongoing. MacroGenics leads this study, which shows 8 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Mar 2022 — Jul 2024 [monthly]
No Longer Available
-
Jan 2021 — Mar 2022 [monthly]
No Longer Available
-
Jun 2018 — Jan 2021 [monthly]
No Longer Available
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
No Longer Available NA
-
Jan 2017 — Feb 2017 [monthly]
No Longer Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MacroGenics
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.